The following "Advanced courses" will be offered on the 11th German Pharma-Tox Summit 2026.
Advanced Course in Toxicology
17 March 2026, 10:00 - 17:00
Venue:
Heinrich Heine University Düsseldorf
Building: 22.01, Roy Lichtenstein
Universitätsstraße 1, 40225 Düsseldorf
Germany
The GT Advanced Course 2026 “Mixture Toxicity” will provide an in-depth overview of the most recent developments in mixture toxicity assessment both from the scientific and regulatory point of view. Session 1 “Mixtures in hazard assessment” of the advanced course will be focusing on the interactions of mixture components and their impact on the hazard characterization and classification of mixtures considering different toxicological endpoints such as acute, repeated dose and specific target organ toxicity as well CMR/ED properties. In Session 2 “Mixture risk assessment”, the impact of the toxicological properties of mixture components on the type and approaches to be applied for mixture risk assessments in dietary and non-dietary use scenarios will be presented and discussed. Finally, the plenary discussion will provide further opportunities for the discussion of hazard and risk assessment of mixtures and the regulatory consequences across horizontal legislations.
Pharmacological protein degradation
18 March 202, 08:30 - 12:00
Venue:
Heinrich Heine University Düsseldorf
Building: 22.01, Roy Lichtenstein
Universitätsstraße 1, 40225 Düsseldorf
Germany
This advanced course introduces pharmacological protein degradation as a therapeutic strategy that eliminates disease-relevant proteins rather than inhibiting their activity. It explores cutting-edge approaches spanning chemical design, targeting concepts, and experimental implementation. Participants will gain insight into emerging degrader modalities and innovative control mechanisms. The session bridges fundamental principles with translational perspectives and assay technologies. Designed for early-career scientists, it offers a compact overview of the field’s current state and future directions and aims to inspire new approaches in drug discovery.